Welcome to our dedicated page for Ufp Technologies news (Ticker: UFPT), a resource for investors and traders seeking the latest updates and insights on Ufp Technologies stock.
UFP Technologies, Inc. (UFPT) delivers innovative custom-engineered solutions for medical device manufacturers and industrial partners through advanced material science and precision manufacturing. This news hub provides investors and industry professionals with direct access to UFPT's official announcements and strategic developments.
Track all corporate communications including quarterly earnings, product innovation launches, and strategic partnerships. Our curated collection features regulatory filings, manufacturing process advancements, and market expansion updates essential for understanding UFPT's position in specialty packaging and component manufacturing.
Key updates cover medical sector innovations, new material applications, and OEM collaboration milestones. Stay informed about UFPT's patented technologies and engineering capabilities that drive solutions for minimally invasive surgery, implant packaging, and aerospace components.
Bookmark this page for real-time updates on UFPT's operational developments and industry leadership. Regularly refreshed content ensures you maintain current awareness of this critical supply chain partner's evolving market role.
UFP Technologies, Inc. (Nasdaq: UFPT) has acquired Contech Medical, Inc., a leader in class III medical device packaging, primarily for catheters and guidewires, with annual sales of approximately $18 million. This acquisition is seen as a strategic fit, allowing UFP to enhance its medical offerings and strengthen customer relationships, as about 70% of Contech’s customers are already UFP clients. The deal is expected to be immediately accretive to earnings and capitalize on the strong growth potential of the medical market.
On September 21, 2021, UFP Technologies, Inc. (Nasdaq: UFPT) announced that CEO R. Jeffrey Bailly and CFO Ron Lataille will present at the Sidoti Fall Virtual Investor Conference scheduled for September 22-23, 2021. The live presentation will start at 10:00 A.M. ET on September 22 and can be accessed here. Additionally, one-on-one meetings with investors will be hosted by the company on the same day. Registration is free and open to all interested parties.
UFP Technologies (Nasdaq: UFPT) announced that CEO Jeff Bailly and CFO Ron Lataille will present at the virtual Midwest IDEAS Investor Conference on August 26, 2021. The company specializes in designing and manufacturing components and packaging for the medical sector, utilizing advanced materials like foams and plastics. UFP also serves diverse markets, including aerospace and automotive. This conference aims to connect quality companies with investment professionals, fostering regional investment communities.
UFP Technologies, Inc. (Nasdaq: UFPT) reported a strong second quarter for 2021, achieving net income of $4.7 million ($0.62 per diluted share), up from $2.3 million ($0.31 per diluted share) in Q2 2020. Sales reached $50.7 million, an 18.8% increase from $42.6 million last year. Year-to-date, net income was $8.9 million, compared to $6.2 million the previous year. Gross margins improved to 26.5%. While challenges in raw material availability and labor shortages persist, the company remains optimistic about growth opportunities and strategic initiatives.
UFP Technologies (Nasdaq: UFPT), a leading designer and manufacturer for the medical market, will participate in the virtual East Coast IDEAS Investor Conference on June 16, 2021. CEO Jeff Bailly and CFO Ron Lataille will present and conduct one-on-one investor meetings. Interested investors can contact Jeff Elliott at Three Part Advisors for participation details. UFP Technologies specializes in creating components using specialized foams and materials, serving various sectors like aerospace, automotive, and industrial markets.
UFP Technologies (Nasdaq: UFPT) reported Q1 2021 net income of $4.2 million ($0.55/share), up from $3.9 million ($0.52/share) in Q1 2020. Sales rose 0.7% to $48.6 million, with a notable performance in Aerospace & Defense and Consumer markets, growing 68% and 62%, respectively. Medical sales, however, fell by 11.5%. Gross profit margin decreased to 25.9%, while SG&A expenses dropped to 15.0%. The company is optimistic about recovery as elective procedures resume and is focused on strategic initiatives for growth.
UFP Technologies, Inc. (Nasdaq: UFPT) announced its participation in the virtual Sidoti Conference on March 24, 2021. Chairman and CEO R. Jeffrey Bailly and CFO Ron Lataille will present at 9:15 AM ET. Investors can access the presentation through the conference portal or visit the company's investor relations section online. UFP Technologies specializes in designing and manufacturing components for the medical market and uses advanced materials and techniques for production.
UFP Technologies reported a net income of $13.4 million ($1.77 per share) for the year ended December 31, 2020, down from $19.8 million ($2.63 per share) in 2019. Sales decreased by 9.6% to $179.4 million. In Q4 2020, net income fell to $4.2 million ($0.55 per share), down from $5.8 million in Q4 2019. Medical sales dropped 6.8% for the year, primarily due to a decline in elective surgeries. However, the Product Development business surged 63%. The company noted improvements in gross margins and expressed optimism for a rebound in sales by Q4 2021.
UFP Technologies (Nasdaq: UFPT) will participate in the virtual Southwest IDEAS Investor Conference on November 18, 2020. Jeff Bailly, CEO, and Ron Lataille, CFO, will present, with the webcast starting at 7:00 am CST. The presentation will be accessible to registered participants via the conference portal and the company's investor relations website. One-on-one meetings with investors will also be hosted throughout the day. Interested investors can contact Jeff Elliott at Three Part Advisors at 972-423-7070 for participation details.
UFP Technologies (Nasdaq: UFPT) reported a third-quarter net income of $3.0 million ($0.40 per diluted share), down from $5.6 million ($0.75 per diluted share) in Q3 2019. Sales declined by 12.3% to $43.3 million, compared to $49.4 million in the same quarter last year. Year-to-date net income fell to $9.2 million from $14.0 million in 2019. Cost-saving initiatives, including workforce reduction, resulted in $5 million in annualized savings. The company holds $20 million in cash and zero debt, maintaining a focus on strategic acquisitions for future growth.
